NCT05081492View on ClinicalTrials.gov

CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

October 18, 2021

Primary Completion Date

March 30, 2026

Study Completion Date

March 30, 2026

Conditions
Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast CarcinomaPrognostic Stage IV Breast Cancer AJCC v8
Interventions
BIOLOGICAL

Oncolytic Virus CF33-expressing hNIS/Anti-PD-L1 Antibody

Given IT

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Imugene Limited

INDUSTRY

lead

City of Hope Medical Center

OTHER